Patient Advocate since 1977.

Leave a comment

Medical cannabis cultivation: could Germany be the next Canada or Netherlands?

Rachel Stern
14 November 2017

Despite the implementation of the legalization of medical marijuana in Germany in March, patients have been met with high prices, supply shortages and persistent taboos. Could domestic growing possibilities help?
After years of chronic back pain stemming from a severe motorcycle crash, Günter Weiglein received special permission from the German government to buy medical marijuana in 2009. The cannabis, inhaled through a vaporizer, eliminated his need for additional, chemically harsher painkillers.

But finding pharmacy costs as a private patient too expensive, he further lobbied his case, and in 2014 was allowed to harvest his own supply in a one-metre tent outside his home in Würzberg, Bavaria.

For Weiglein, a full victory should have arrived on March 10th this year, when Germany legalized medical marijuana for patients with a prescription. The new law mandates that insurance companies cover the costs of upwards of 100 grams of the flower per month for chronically and terminally ill patients.

But instead, more hurdles arose. Now some patients are waiting up to a few months to get their hands on the drug, imported at even higher prices from already-established markets in Canada and the Netherlands. Many doctors are furthermore wary of divvying out prescriptions for the stigmatized substance, and insurance companies are reluctant to pay. Home-grown, meanwhile, became strictly forbidden.

“Now it’s supposed to be easier because it’s in the doctor’s hands,” said Weinglein, who has a court date scheduled in late November to decide if he has permission to grow his own supply again. “But the problem is that the majority don’t know anything about it, don’t want to have anything to do with it, and are afraid that they could be put in some sort of corner by their colleagues.”

Growing in Germany

This year there have been high hopes that domestic growth could take on a larger scale. In April, Germany’s Federal Institute for Drugs and Medical Devices (BfArM) put out a bid seeking 10 companies to initially grow 2,000 kilograms of marijuana per year for medicinal purposes, and 6,600 kilograms by 2022. The agency has not yet publicly released a list of who the approved growers, slated to start production in 2019, will be.

One Canadian company, ABcann, eagerly lined up to be part of the bidding process by setting up German subsidiary headquarters in Schönefeld just outside of Berlin and listing itself on both the German and American stock exchanges this summer.

They announced plans to invest €40 million and create 400 new jobs in a sprawling indoor plantation of 10,000 square metres in the bucolic Lusatia region of Brandenburg. Yet in November, the company put their plans on hold after it was reportedly announced that they would not be a finalist in the initial tender bid.

“Right now the patient numbers are growing and the product numbers are really too low,” John Hoff, the former CEO of ABcann Germany and a patient himself, told The Local in October. “So that’s why we have to have something here.”

Reducing high costs

The number of Germans receiving a prescription for medical cannabis has increased tenfold since before March this year, when Germany granted permission to only 1,000 special cases such as Weiglein’s, estimates Georg Wurth of the German Hanfverband (Hemp Association). The number is expected to increase by 5,000-10,000 a year over the next few years.

“The growth of medical marijuana in Germany will be part of the solution to improving supply and cost issues,” says Wurth. Currently pharmacies carry about 15 strains of marijuana, out of hundreds of potential varieties.

According to the new law, any of the 90 percent of Germans covered by public health care are eligible to receive a prescription. Yet many patients still have to pay high costs out of pocket and are unsure of when or if they will be reimbursed. A few patients have even sued their insurance companies due to their unwillingness to pay.

About half of all applications for medical cannabis are turned down by the insurance companies, says Cologne-based Cannamedical spokesperson Julija Murawskij, pointing out that they are not deemed “serious enough.”

“Many patients often have problems finding a doctor to take them seriously,” says Murawskij, whose company will begin importing a greater amount of cannabis leaves from Canada to meet the supply bottleneck. “When they finally get a prescription, they can submit this to the health insurance company for reimbursement.”

There are a select number of doctors in Germany specializing in prescribing medical marijuana, but they also have a backlog of patients. Brandenburg-based Dr. Franjo Grotenhermen, chairman of the group Cannabis as Medicine eV, told The Local he has patients who have been waiting since December 2016 to see him.

But regulations don’t make it easy for doctors either. Silke Will, a researcher from Growholistic near Stuttgart, explained that it can be difficult for patients to receive a prescription from a doctor in the first place. They can only write one if a patient is Austherapiert, she said, meaning they have tried every other possible option first, and then receive permission from the Bundesopiumstelle or Germany’s Federal Opium Agency.

The supply shortage and difficulties gaining access to the drug have led many cannabis patients in Germany to turn to the black market where cannabis costs about €10 a gram, says Will.

“A lot of people don’t want to go to the very strong chemical medication,” says Will, who is conducting research for a new organic fertilizer product for medicinal marijuana. “But they have to before getting natural medication, and this is a very bad situation for a lot of patients. The tough time of getting it as a medicine drives them back to Holland or wherever.”

In the Netherlands, one dose of five grams of medical marijuana is estimated to cost €30 versus €125 for the same amount in Germany.

Making it easier for patients

In the past year alone, nearly 170 kilograms of medical marijuana have been imported into Germany. Already in 2016, Spektrum Cannabis, formerly known as MedCann Gmbh, began bringing dry cannabis flowers from Canada into Germany. Once in the country, they led quality control checks at their laboratories and distributed it to pharmacies.

“We were the first ones to start the party here,” says CEO Dr. Pierre Debs from his office near Heidelberg. “We can buy and import from any country that has a federal cannabis agency. If Germany starts producing cannabis and it’s available for us to buy and distribute, then why not?”

Before cannabis can be widely grown and distributed in Germany though, attitudes have to change toward it, says Will. “Most people in Germany still think that cannabis is part of the Schmuddelecke,” she says, using the colloquial German word for a “dirty place.”

Advocating for a change against this attitude, hundreds of activists, business people, politicians and even a couple policemen gathered for the Hanfverband’s first cannabis conference on November 3rd to the 4th in Berlin. The conference was filled with panels discussing the need to legalize cannabis – and how doing so would reduce taboos of it as a medicine.

One attendee, Frankfurt-based Marguerite Arnold, creator of MedPayRx – a blockchain-based health application that is intended to help patients legally access and afford cannabis and other drugs. Expected to launch next year, the startup has already snagged a second place finish at the Maintech Summit at the Frankfurt School of Finance and Management and CannaTech in London in October.

“If sick people who take cannabis can better manage their conditions starting with chronic pain or diabetes or epilepsy,” says Arnold, “this will be a huge win for public health insurance companies, if not the economy.”

“Not to mention people’s lives beyond that.”


Leave a comment

Lawsuit Delays the Cultivation of Medical Cannabis in Germany – by MICHAEL KNODT

German company Lexamed has successfully filed a lawsuit against the Federal Institute for Drugs and Medical Devices’ (BfArM) selection process for medical cannabis cultivation in Germany, delaying selection and implementation of the country’s medical cannabis cultivation program. Lexamed produces wheelchairs, rollators, and electric drives and wanted to invest in the cultivation of medical cannabis as early as possible, but at the end of June, BfArM rejected the company’s application.

At the beginning of June, 118 companies had applied for a medical cannabis cultivation-license in Germany. Until Lexamed’s appeal against the application criteria is heard by the Düsseldorf Higher Regional Court Dec. 20, official application evaluations, which should have been decided in October, are suspended.

Criteria Favors Experience

Generally, the BfArM regulates any production that must be done in compliance with the U.N.’s Single Convention on Narcotic Drugs of 1961, an international treaty that set regulations for the supply and production of specific drugs, including cannabis.

Cultivation applicants are required to meet many criteria to prove their capacity in the field of growing, processing, and supplying medical cannabis or growing phytomedicinal products in general. In a staged lottery, ten licenses are distributed by drawing lots among all applicants fulfilling the required criteria. For every hundred kg of cannabis grown, applicants earn 10 points, with a maximum of 40 points. So, if an applicant can prove they’ve already grown 200 kg of medical cannabis within the last three years, they will have already satisfied two-thirds of the minimum criteria. A maximum of 20 additional points is awarded based on references for the other herbal medicinal products.

If fewer than ten companies meet the requirements, licenses will be given to the applicants with the most points. Each cultivator is expected to deliver 200 kg of medical cannabis per year. For the period from 2019 to 2022, around 6.6 tonnes were scheduled for cultivation. To ensure each applicant is able to produce enough cannabis for a period of 65 months, up to seven lots per applicant may be awarded.

In order to achieve the maximum score of 60 points, candidates must demonstrate experience in growing at least 50 kilograms of medicinal cannabis within the last three years and have references in the cultivation field.

Only applicants who could prove they had already made finished drugs from medical herbs could earn the highest score.

Additionally, cannabis “made in Germany” will be subject to some of the strictest standards. In the Netherlands and Germany, test results for THC and CBD content must be within a +/- 10-percent deviation. In Canada and the Netherlands, the allowable deviation is 20 percent. For example, if a product is expected to test at 20 percent THC based on any previous testing, but tests at 35 percent, that’s allowable in Canada or the Netherlands as long as the THC percentage is clearly labeled on the product. In Germany, that crop would fail, so even if producers are awarded licenses to cultivate, they have very little room for error.

German Companies Alone Have No Chance

The catch is that applicants who did not partner with experienced companies from Canada, the Netherlands or Israel — countries with companies that meet the 200 kg cultivation criteria — would have been able to get in front of only 20 of the 60 possible points, putting them at a disadvantage. Partner companies from the United States did not meet the criteria, because cannabis production in several states is not subject to federal regulation, which, according to the Single Convention, renders the activities of U.S. producers generally illegal.

Numerous critics claim the selection criteria is tailored for large Phyto-Pharma companies and foreign investors. In principle, German startups have no chance of fulfilling the conditions given by the Federal Republic of Germany, because there has been no legal cultivation of cannabis in Germany. German cultivation activities could not be cited as a reference to earning the points necessary for their application to be approved.

“If the federal government had not tried to exclude German start-ups, various license-holders would already have taken first concrete steps to prepare production. Now there is the possibility that there will be significant delays,” Hanfverband CEO Georg Wurth told Marijuana.com.

What Now?

Until the objection is heard, the selection process is at a standstill. The judges considered the complaint as “not obviously hopeless” in September. If they agree with Lexamed’s lawyers, the current application procedure will be obsolete and the BfArM will need to develop other criteria, giving opportunities to companies that have not yet been able to grow cannabis due to the legal situation in their country.

Such a delay would throw the industry’s schedule back and delay the first crop for at least six months, aggravating an already unsatisfactory supply situation. If the litigious company’s complaint is dismissed, the first cultivation licenses, which should have been issued a month ago, could follow in January 2018.

Photo courtesy of Allie Beckett

Leave a comment

Prohibition Partners, suggests that Europe will become the largest legal cannabis market in the world once all countries have introduced legislation and regulation over the next five years.

SOURCE Prohibition Partners

LONDON, November 6, 2017 /PRNewswire/ —

A new report from industry advisors, Prohibition Partners, suggests that Europe will become the largest legal cannabis market in the world once all countries have introduced legislation and regulation over the next five years.

Cannabis is set to become the major global industry of the post-digital generation. It will drive economic and employment growth as well as having a significant impact on a wide range of social issues.

The impressive financial performance of North American cannabis companies is already drawing in institutional investors – even before US federal legislation.

However, Europe is quickly catching up with a record number of countries introducing medical cannabis legislation already this year. Most governments understand the medical and tax benefits so are moving fast to position correctly for this opportunity. Buoyed by a shift in legislation and ground breaking returns, the European cannabis industry represents a very unique and rewarding opportunity.

The European Cannabis Report™ (2nd Edition) explores the complex regulatory environment while providing a detailed analysis of 15 key markets across the medical, recreational and industrial sectors.

About Prohibition Partners

We are trusted advisors to the legal cannabis industry. We believe Europe will gradually open over the next three to five years to become the largest cannabis market in the world.

However the challenge will be combining traditional values and advocacy with the level of corporate and professional knowledge required to build robust and scalable businesses.

We work with investors, entrepreneurs and regulators to identify, qualify and maximise the many opportunities in this emerging frontier. Our reliable and credible insight is maturing the conversation and opening up the industry.

More Information

Download Report for Free – https://www.prohibitionpartners.com/europeancannabisreport/

Read The Report Here

Media Contact:
Stephen Murphy (Partner)

©2017 PR Newswire. All Rights Reserved.

Leave a comment

Statement by German Foreign Minister Gabriel on the 500th anniversary of the Reformation

The Reformation and its effects changed the world and our societies far beyond Germany and led Europe into the modern era. We owe our current humanistic, enlightened world view not least to the reformers and their work.

Today’s conflict-ridden world is in search of direction. We are witnessing increasing authoritarianism and resurging nationalism. As a result, values associated with the Reformation, such as peace, freedom and responsibility, are under pressure. When we look back at 500 years of the Reformation tomorrow, we will do so in the knowledge that our country’s foreign policy must stand up for these values more than ever before.

The answer to these challenges cannot be to withdraw to a national bubble. Instead, we must recall Martin Luther’s call to “get involved!”. With this in mind, we must work resolutely for equity and peace worldwide and seek dialogue with those who do not share our values. In this context, we also aim to make greater use of religions’ peacemaking potential in our foreign policy than we have done so far, with the aim of fostering equity and justice in societies around the world.


Leave a comment

MERKEL GETS RELIGION on the 500-year anniversary of Martin Luther’s Reformation project. Legalized marijuana in Germany now on the horizon.

Cannabis Consultant in Germany


October 31, 2017

As many Americans start the day making plans for Halloween 2017, the folks here in Germany have the day off of work to celebrate the 500-year Anniversary of Martin Luther’s project to reform German society. Surprisingly, the newspapers today also announced Chancellor Angela Merkel’s intentions, along with her new coalition partners called the “Jamaican coalition” to consider legalizing marijuana.

Seems an unintended benefit of the AFD’s victories in the last elections, is the CDU ruling party is now more receptive to working with those with divergent views in order to maintain their leadership position.

Could this really be the start of the Reformation of the 20th century drug laws in Germany and beyond?

Has the work of the DHV in Berlin and their partners finally started to pay dividends?

Was the signing of the BERLIN PEACE ACCORDS http://www.berlinpeaceaccords.de , which begins with “We the people of the Year 2017 do…
Hereby declare that it is our inalienable basic human right to have the freedom to grow, medicate and enjoy the plant we call Cannabis, without any governmental limitations.
We demand our plant has no more regulations or limitations than a tomato plant…..” really have been the precursor to this historic moment?

Good questions, time will tell, but for sure our collective efforts as cannabis business executives are starting to pay dividends.

The month of October had started off with over 350 doctors, scientists, investors and industry professionals waking up in view of the massive Cologne Cathedral, which is truly an amazing sight to see in person! The International Association for Cannabinoid Medicines’ (IACM) CANNABINOID CONFERENCE was held in downtown Cologne bringing together experts from Canada, Australia, Germany, and from throughout the world. Their website is http://www.cannabis-med.org and three take-aways were:

The idea that “Marijuana has no medicinal value” was pretty much, fully debunked 😊

The breath and quantity of existing “clinical trials” on our plant is amazing.

Meeting Josh Stanley, whose company has arguably helped more medical marijuana patients than anyone, was a privilege. CW Hemp’s team continues to lead the industry in many ways,…and additionally they are simply very cool people.

Later in the month, the folks from the regulatory and compliance organization ASTM came to Berlin for a 2-day intensive session for their new “Technical Committee D37 on Cannabis” section. You know we are becoming a real industry when 2 days is spent talking only about compliance related issues. Half the group was from Germany, including executives from the first licensed marijuana testing facility located within Germany, scientists from the University of Berlin currently working on marijuana clinical trials, and a few of the leading homegrown companies on the front lines including ABCann Germany, MH Hemp, Pedanois, and two guys who reminded me of what a young Ed Rosenthal would be like. 😊

So as November 2017 begins, many of us will meet in Berlin this weekend for the first annual DHV Convention. Their website is https://hanfverband.de and they are unequivocally the leading organization for marijuana reform in Germany today. This convention will probably confirm these four truths of the marijuana landscape in Germany today:

Canadian firms are kicking butt!
They understand the requirement of GMP certification, their government is supportive of providing qualified companies an export license for their THC-based products, and their executives are damn smart.

German firms are coming of age, are intelligent and committed.
The first DHV convention will be highlighting the work of patient advocates, industry professionals, knowledgeable physicians and forward-looking politicians involved in building this new industry within the German borders.

The European, South American, African, Israeli and Australian firms are all actively making plans to succeed.
Governments, investors, and executives from throughout the world are looking at Germany and making their plans to enter the European market with its 750+ million potential customers. They are forming strategic partnerships, investing in commercial facilities, and making Europe a priority for 2018.

The USA is an abysmal no-show in the game.
America started the war on Marihuana last century, and somehow tries to keep the war alive today. Scientist, Stoners and Society have evolved quite a bit since the 1930s. The Germans have taken note, changed course in their direction, and their people will be better off as a result.

Maybe now it’s time for President Trump get religion and start his own Marijuana Reformation project?

– Philip J. Cenedella

Leave a comment

Germany’s largest legal cannabis plantation – by VICE Magazine



Germany’s largest legal cannabis plantation
Tim Geyer
Oct. 17 2017, 3:20 pm
Because of grass dealings, Christoph Roßner had already been in prison for five months. Today he works with Bavarian politicians.

This is not really a loose work place, even if grass is to be cultivated, says Christoph Roßner. The Atombunker, before which he stands, is squeezed between car parks and fields in the Allgäu countryside like a stranded oil tank. Here, from the former Fliegerhorst Memmingerberg NATO would have led the nuclear counterattack, had the Cold War escalated. Today the entrepreneur wants to breed cannabis in the bunker. Green haze instead of black rain – within sight of a federal police station and with the blessing of the Bavarian government. Since the beginning of the year, cannabis is legal on prescription in Germany and Rossner’s sentiment is that of a brewer’s owner after the end of the prohibition: “We have the chance to become one of the biggest players in the international cannabis market.”

Alone for 2015, the German Monitoring Center for Drugs and Drug Abuse (DBDD) counts almost five million Germans who have consumed cannabis at least once during the last twelve months. The dark figure should be even higher. Activists and businessmen have taken this first step towards legalization. Christoph Roßner is both. And also looks like this: black jacket over black sweater, the gray hair tamed to the horse tail. Business in the front, party in the back.

One of the many lock gates between the individual bunkers
From the war machine to the grass factory

The bunker, a 50-meter-long, 15-meter high colossus, with its aerial storms acts like a medieval fortress. From 1985, the Luftwaffe soldiers of the Jagdbombersgeschwader 34 were sitting here, servicing the control systems for the nearby rocket silos. “This bunker is safer than a nuclear waste disposal site, but we want to grow plants here,” says the 47-year-old. He has previously registered with the neighboring Federal Police Station on the visit of the journalists.

The Panzertor groans aside. 175 tons of hardened steel, eight meters wide, nearly one meter thick. A siren howls like a submarine on a dive. Through the opening one reaches the actual bunker, which surrounds the outer wall as the reactor coherent of Chernobyl. Then another lock door, another 30 centimeters of steel. Later, 15 employees of Roßner’s company Bunker PPD, which he wants to adjust, will change the street clothes against overalls without bags and scan their fingerprints. The few, the income, will be nothing to take with. Roßner leads past former team rooms and the radio center, a five-meter-thick steel-concrete ceiling above us. You go ducked, even though you do not have to.

But no matter how many nights Roßner is working on his business plans, in the end others decide: the Federal Institute for Drugs and Medical Devices and the Bundespiumstelle, which is subordinate to him. Anyone who wants to produce or use drugs in Germany must either talk to them or seek a good lawyer. But once the TÜV seal of the Panzertür has expired, once the officials discover a tiny mistake in a request: the bureaucrats are editing Roßner, the changing Würgreiz for CSU politicians, so meticulously as if they Franz Josef Strauss’ last will.

Where the radio had previously been monitored, a cannabis laboratory could soon be available
From activist to cannabis entrepreneur

Roßner knows this. For the last three decades he has been working on the legalization of cannabis. Two key experiences are the reason: at 17 he smokes his first joint. He notes: Kiffen helps him to curb his hyperactivity. A year later a steel carrier crushed his left shoulder during his training as an industrial mechanic. Against the chronic pain smokes Roßner cannabis. To this day, now on recipe. “If you like, I’m just tight,” he says. In 1994, a friend of Roßner, who suffers from epilepsy, finds out that marijuana dampens his attacks. Roessner’s sister also suffered from epilepsy. For them, this knowledge comes too late. Two years before, she committed suicide. “I could have helped her,” says Rossner.

From this moment on, he is on a mission: He is worried about marijuana to help others, he says. “Illegal research” he calls this. At that time, as today, cannabis is prohibited by law in Germany. It is only since 1 March 2017 that doctors can prescribe – even without the hard-to-obtain exemption. Although in 1994, the Federal Constitutional Court ruled that a small quantity of cannabis can be carried with no prescription – depending on the federal state, between five and ten grams – this verdict does not, however, protect against criminal prosecution. This is what the courts alone decide. Roessner also knew about the risk, especially in Bavaria, When it is rumored that he is running a kind of private hemp pharmacy, more and more people are coming. Rheumatics, neurodermatitis, chemotherapy patients. And some policemen.

If at any time the electricity should fail, Roßner can take advantage of four diesel generators to supply his cannabis lantern with light
Roßner is sentenced: two years and one month. He spends five months in prison and four in therapy. It’s been 17 years now. When he rages, he knocks again at his doorstep. Still, people who have pain are coming. Roßner does not do any illegal business, he continues to believe in the medical benefits of cannabis. Together with the Chair of Chemistry at the Technical University of Munich and the University of British Columbia, he is currently preparing a study to investigate the effects of the most important medicinal hemp varieties and to develop quality standards for them. 150 patients he wants to provide cannabis from his bunker. Will the study and the necessary hemp cultivation be approved, this would be his first decisive step to enter the medical cannabis market. The study is intended to prove that he, the ex-prisoner, is serious.

Politicians, investors and business bosses listen to him

By working with the universities, Roßner hopes that the newly established state-owned cannabis agency will choose him to produce state-certified grass. The agency is to provide patients with marijuana from Germany and is looking for producers all over Europe. In addition to Rossner, other German entrepreneurs are also applying, for example SensHemp from Berlin and Hanf AG from Hamburg. 2,000 kilograms per year, the agency estimates, would have to grow on German plantings in 2021 and 2022 to supply all patients. Roßner believes that German patients need six times a year: over 12 tonnes of grass. If no one has to apply for an exemption, but only needs a prescription, more patients will take this step, he is sure. In addition, it would not be worth it to build a plant worth several million euros. But without permission for the study, he could set up his bunker to a very unpleasant country house.

Plantation air could soon flow through the ventilation towers
Just a strong CSU conservative helps him with his plan. Franz Josef Pschierer, State Secretary in the Bavarian Ministry of Economic Affairs, will bring him together with entrepreneurs and politicians from Bavaria in 2016. Roßner tells them about the unused economic potential, possible tax revenues and savings in the police and courts. “Without the help of the Bavarian government, no one would listen to me,” he says. He is now planning his cannabis breeding plant with ThyssenKrupp – and is holding talks with internationally active hedge funds. If they invest in it, the Free State of Bavaria could subsidize its business with about a quarter of a million euros. From tax money. Marijuana sponsored by Horst Seehofer.

In many places in the bunker the soldiers have left something behind
While Roßner sketched his battle plan for the next months, we descend deeper into the airtight crypt. There is neither mobile phone reception nor spiderwebs. Comic paintings on the walls testify to what the soldiers were busy with when they were bored to wait for the Third World War. In one room there are vault chambers, large as overseas containers. Here the mother plants could grow. “Lamps clean, connect ventilation, let’s go,” says Roßner, “more perfect conditions than here you will find nowhere.” A high-security laboratory is to move into the former squadron headquarters. Here, chemists could clone potent cannabis varieties. Next to it stands an industrial furnace, in which former toxins were destroyed at 900 degrees. In the future, the most serious of these will be burned. A few security doors: the space for the cuttings. “We start with 80 different varieties,” Roßner says self-confidently, as if he had the approval already.

In these cabinets Roßner wants to breed young plants
Race with the Dutch

Sometimes Christoph Rossner would ask the same as the early fans of Cherry Coke or anal whitening: When will the backward-looking Germans finally understand what the Americans have long been celebrating? In 29 out of 50 US states , medical cannabis has been allowed or grass has been fully legalized. In 2016, the industry generated sales of 6.7 billion US dollars . Until it is so far in Germany, Rossner will still have to smoke a few blunts on the recipe.

At the beginning of the year, he was sitting with his lawyers to prepare a lawsuit against the Federal Institute for Drugs, he tells us as we step out of the darkness of the bunker. The agency has asked potential medical producers that they have already grown, processed and delivered at least 50 kilograms over the last three years. How is he to apply, if exactly that in Germany so far was illegal, Roßner curses. It is not easy to get a mission in Germany for something that does not really exist at all.

Meanwhile, the authorities want to improve – a small victory, but Rossner is running out of time. The Dutch company Sensi Seeds systematically purchases small cannabis producers in the USA and is now pushing into the German market. Roßner does not want to be bought up. His research project will start in March, followed by commercial operations. He wants to make money himself and make the world a bit better with nothing but a few plants from a Bavarian atomic bomb.

Follow VICE on Facebook , Instagram and Snapchat .